Literature DB >> 8551805

Mutations of the p53 gene in myelodysplastic syndrome and overt leukemia.

N Mori1, H Hidai, J Yokota, M Okada, T Motoji, K Oshimi, H Mizoguchi.   

Abstract

We analysed p53 mutations in 24 patients with myelodysplastic syndrome (MDS) and overt acute myeloid leukaemia after a period of MDS, using polymerase chain reaction-single strand conformation polymorphism analysis. In exons 5 to 8, mobility shifts were detected in five of the 24 patients. Sequence analysis was subsequently performed, and four missense mutations (16.7%) and one silent nucleotide substitution were identified. Patients harbouring mutations were characterized as having advanced disease. Loss of the wild type allele was observed in three of the four patients with missense mutations. No mobility shifts of the N-ras or FMS gene were detected in these four patients. We next analysed the correlation of the p53 mutations with the progression of MDS in three patients. The mutation was accompanied by the progression in two of the three patients. These findings suggest that mutations of the p53 gene are associated with progression in some cases of MDS, while being compatible with stable disease or clonal evolution in others.

Entities:  

Mesh:

Year:  1995        PMID: 8551805     DOI: 10.1016/0145-2126(95)00058-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Scientific comment on tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.

Authors:  Elvira Deolinda Rodrigues Pereira Velloso
Journal:  Rev Bras Hematol Hemoter       Date:  2014-04-04

2.  Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.

Authors:  Fernando Ramos; Cristina Robledo; Francisco Miguel Izquierdo-García; Dimas Suárez-Vilela; Rocío Benito; Marta Fuertes; Andrés Insunza; Eva Barragán; Mónica Del Rey; José María García-Ruiz de Morales; Mar Tormo; Eduardo Salido; Lurdes Zamora; Carmen Pedro; Javier Sánchez-Del-Real; María Díez-Campelo; Consuelo Del Cañizo; Guillermo F Sanz; Jesús María Hernández-Rivas
Journal:  Oncotarget       Date:  2016-05-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.